BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 21409446)

  • 1. Serotype-specific and cross-reactive neutralizing antibody responses in cynomolgus monkeys after infection with multiple dengue virus serotypes.
    Ito M; Katakai Y; Ono F; Akari H; Mukai RZ; Takasaki T; Kotaki A; Kurane I
    Arch Virol; 2011 Jun; 156(6):1073-7. PubMed ID: 21409446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-dependent enhancement of dengue virus infection in vitro by undiluted sera from monkeys infected with heterotypic dengue virus.
    Ito M; Mukai RZ; Takasaki T; Kotaki A; Kurane I
    Arch Virol; 2010 Oct; 155(10):1617-24. PubMed ID: 20644969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Analysis of serum neutralizing antibody response in patients with primary dengue virus type 1 infection].
    Hu D; Li J; Wang D; DI B; Qiu L; Wang Y; Ding X; Che X
    Nan Fang Yi Ke Da Xue Xue Bao; 2012 Dec; 32(12):1773-6, 1791. PubMed ID: 23268408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies.
    Tsai WY; Durbin A; Tsai JJ; Hsieh SC; Whitehead S; Wang WK
    J Virol; 2015 Jul; 89(14):7348-62. PubMed ID: 25972550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genotype-specific and cross-reactive neutralizing antibodies induced by dengue virus infection: detection of antibodies with different levels of neutralizing activities against homologous and heterologous genotypes of dengue virus type 2 in common marmosets (Callithrix jacchus).
    Azami NAM; Moi ML; Ami Y; Suzaki Y; Lim CK; Taniguchi S; Saijo M; Takasaki T; Kurane I
    Virol J; 2018 Mar; 15(1):51. PubMed ID: 29587780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective serological study on sequential dengue virus serotypes 1 to 4 epidemics in Tainan City, Taiwan, 1994 to 2000.
    Chang SF; Huang JH; Chen LK; Su CL; Liao TL; Chien LJ; Lin TH; Su CJ; Shu PY
    J Microbiol Immunol Infect; 2008 Oct; 41(5):377-85. PubMed ID: 19122918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct and indirect interactions in the recognition between a cross-neutralizing antibody and the four serotypes of dengue virus.
    Lisova O; Belkadi L; Bedouelle H
    J Mol Recognit; 2014 Apr; 27(4):205-14. PubMed ID: 24591178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human monoclonal antibodies to neutralize all dengue virus serotypes using lymphocytes from patients at acute phase of the secondary infection.
    Setthapramote C; Sasaki T; Puiprom O; Limkittikul K; Pitaksajjakul P; Pipattanaboon C; Sasayama M; Leuangwutiwong P; Phumratanaprapin W; Chamnachanan S; Kusolsuk T; Jittmittraphap A; Asai A; Arias JF; Hirai I; Kuhara M; Okuno Y; Kurosu T; Ramasoota P; Ikuta K
    Biochem Biophys Res Commun; 2012 Jul; 423(4):867-72. PubMed ID: 22713454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dissecting the human serum antibody response to secondary dengue virus infections.
    Patel B; Longo P; Miley MJ; Montoya M; Harris E; de Silva AM
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005554. PubMed ID: 28505154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-serotype neutralization of dengue virus in Aotus nancymae monkeys.
    Kochel TJ; Watts DM; Gozalo AS; Ewing DF; Porter KR; Russell KL
    J Infect Dis; 2005 Mar; 191(6):1000-4. PubMed ID: 15717278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dengue virus infection-enhancing activity of undiluted sera obtained from patients with secondary dengue virus infection.
    Moi ML; Takasaki T; Saijo M; Kurane I
    Trans R Soc Trop Med Hyg; 2013 Jan; 107(1):51-8. PubMed ID: 23296697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dengue virus neutralization and antibody-dependent enhancement activities of human monoclonal antibodies derived from dengue patients at acute phase of secondary infection.
    Sasaki T; Setthapramote C; Kurosu T; Nishimura M; Asai A; Omokoko MD; Pipattanaboon C; Pitaksajjakul P; Limkittikul K; Subchareon A; Chaichana P; Okabayashi T; Hirai I; Leaungwutiwong P; Misaki R; Fujiyama K; Ono K; Okuno Y; Ramasoota P; Ikuta K
    Antiviral Res; 2013 Jun; 98(3):423-31. PubMed ID: 23545366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort.
    Katzelnick LC; Montoya M; Gresh L; Balmaseda A; Harris E
    Proc Natl Acad Sci U S A; 2016 Jan; 113(3):728-33. PubMed ID: 26729879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination.
    Nivarthi UK; Kose N; Sapparapu G; Widman D; Gallichotte E; Pfaff JM; Doranz BJ; Weiskopf D; Sette A; Durbin AP; Whitehead SS; Baric R; Crowe JE; de Silva AM
    J Virol; 2017 Mar; 91(5):. PubMed ID: 28031369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection of Rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination.
    Sun W; Nisalak A; Gettayacamin M; Eckels KH; Putnak JR; Vaughn DW; Innis BL; Thomas SJ; Endy TP
    J Infect Dis; 2006 Jun; 193(12):1658-65. PubMed ID: 16703509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B Cell Responses during Secondary Dengue Virus Infection Are Dominated by Highly Cross-Reactive, Memory-Derived Plasmablasts.
    Priyamvada L; Cho A; Onlamoon N; Zheng NY; Huang M; Kovalenkov Y; Chokephaibulkit K; Angkasekwinai N; Pattanapanyasat K; Ahmed R; Wilson PC; Wrammert J
    J Virol; 2016 Jun; 90(12):5574-85. PubMed ID: 27030262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of Individuals from a Dengue-Endemic Region Helps Define the Footprint and Repertoire of Antibodies Targeting Dengue Virus 3 Type-Specific Epitopes.
    Andrade DV; Katzelnick LC; Widman DG; Balmaseda A; de Silva AM; Baric RS; Harris E
    mBio; 2017 Sep; 8(5):. PubMed ID: 28928210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High frequency of pre-existing neutralizing antibody responses in patients with dengue during an outbreak in Central Brazil.
    de Teive E Argolo AF; de Rezende Féres VC; Cordeiro MT; da Silveira LA; Guilarde AO; de Azevedo Marques ET; de Souza WV; Martelli CM
    BMC Infect Dis; 2016 Oct; 16(1):546. PubMed ID: 27717314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dengue virus infection-enhancement activity in neutralizing antibodies of healthy adults before dengue season as determined by using FcγR-expressing cells.
    Ly MHP; Moi ML; Vu TBH; Tun MMN; Saunders T; Nguyen CN; Nguyen AKT; Nguyen HM; Dao TH; Pham DQ; Nguyen TTT; Le TQM; Hasebe F; Morita K
    BMC Infect Dis; 2018 Jan; 18(1):31. PubMed ID: 29321001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Detection of lymphoproliferative response in monkeys innoculated with dengue 4 virus].
    García G; Alvarez M; Santana E; Martínez JR; Alvarez A; Rodríguez R; Guzmán MG
    Rev Cubana Med Trop; 2003; 55(1):27-9. PubMed ID: 15849949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.